Long Daniel D. 4
4 · Septerna, Inc. · Filed Feb 10, 2026
Research Summary
AI-generated summary of this filing
Septerna SVP Daniel D. Long Receives 80,000-Share Option Award
What Happened
Daniel D. Long, Senior Vice President, Drug Discovery at Septerna, was granted a derivative award covering 80,000 shares on February 6, 2026. The Form 4 reports the acquisition as a derivative at $0.00 per share (i.e., an option award rather than an open‑market purchase or sale). No exercise or sale occurred in this filing.
Key Details
- Transaction date: 2026-02-06; Form 4 filed: 2026-02-10 (timely filing).
- Security: derivative (option award) for 80,000 shares reported at $0.00 per share.
- Vesting (footnote): 2/48 of the option shares vest on March 1, 2026; the remaining shares vest in 46 substantially equal monthly installments thereafter, subject to continued service.
- Shares owned after transaction: not specified in the filing.
- Exhibit noted: 24.2 (Substitute Power of Attorney).
- Transaction type: Award/Grant (code A on Form 4); not an exercise or sale.
Context
This entry reflects an equity incentive grant (typical for executive/employee retention and compensation). As a derivative award, it does not represent an immediate purchase or sale of common stock; value is realized only as options vest and are exercised (if exercised). The filing appears timely under Section 16 reporting rules.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-02-06+80,000→ 80,000 totalExercise: $25.41Exp: 2036-02-05→ Common Stock (80,000 underlying)
Footnotes (1)
- [F1]2/48th of the shares subject to such option shall vest and become exercisable on March 1, 2026 and the remaining shares subject to the option shall vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.